Companies /Healthcare

AbCellera Biologics Inc

NASDAQ: ABCL Biotechnology
$12.33
â–² $0.09 (+0.76%) today
Markets open · 2:57pm ET

Q3 2025 Earnings

Reported Nov 6, 2025, 4:21pm ET · SEC source
$-0.19
Miss −17.28%
EPS · est. $-0.16
$9.0M
Beat +41.40%
Revenue · est. $6.3M
−6.1%
Trailing market
ABCL vs S&P since report
1 quarter
Consecutive EPS misses

Market Reaction

% change · around the report
−16%−8%0Nov 6Nov 7report 4:21pm ETearnings+0.2%−6.7%
−16%−8%0Nov 6Nov 7earnings+0.2%−6.7%
ABCL −6.7%S&P 500 +0.2%
−21%−14%−7%0Nov 6Nov 7report 4:21pm ETearnings−0.0%−6.7%
−21%−14%−7%0Nov 6Nov 7earnings−0.0%−6.7%
ABCL −6.7%NASDAQ −0.0%
−18%−9%0+9%Nov 5Nov 14report 4:21pm ETearnings+0.1%−14.0%
−18%−9%0+9%Nov 5Nov 14earnings+0.1%−14.0%
ABCL −14.0%S&P 500 +0.1%
−18%−9%0+9%Nov 5Nov 14report 4:21pm ETearnings−0.4%−14.0%
−18%−9%0+9%Nov 5Nov 14earnings−0.4%−14.0%
ABCL −14.0%NASDAQ −0.4%
−13.69%
Day of report
+3.07%
Next session
−5.63%
One week
−3.58%
30 days

S&P 500 over the same 30 days: +2.47%.

Did ABCL Beat Earnings? Q3 2025 Results

AbCellera Biologics delivered a mixed third quarter, posting revenue of $8.96 million that cleared the $6.33 million consensus by 41.40% and grew 37.6% year over year, while its loss per share of $0.19 came in wider than the $0.16 analysts had expected, missing by 17.28%. The earnings shortfall traces directly to a sharp acceleration in R&D spending, which climbed to $55.03 million from $40.97 million a year ago as the company channeled resources into its internal pipeline, including $15.00 million directed to two proprietary programs in the quarter alone. Despite the deeper net loss of $57.12 million, the operating loss narrowed to $76.28 million from $93.66 million, aided by a dramatic drop in depreciation and impairment charges as platform investments near completion. With lead candidates ABCL635 and ABCL575 advancing through Phase 1 trials and roughly $680 million in available liquidity, AbCellera is positioning its substantially completed platform as the foundation for a broadening clinical pipeline, including newly nominated development candidate ABCL688.

Key Takeaways
  • Research fees revenue grew to $8.8 million from $6.3 million year-over-year
  • Greater proportion of R&D expenses directed toward internal programs, including $15 million on two internal programs in Q3
  • Depreciation, amortization, and impairment charges decreased significantly to $5.2 million from $36.9 million year-over-year

“AbCellera successfully delivered on two corporate priorities this quarter by starting activities at our new clinical manufacturing facility and substantially completing our platform investments.”

AbCellera Biologics CEO, on the earnings call

Forward Guidance & Outlook

AbCellera will continue to prioritize advancing its two lead programs (ABCL635 and ABCL575) through Phase 1 clinical studies and building its pipeline, including progressing ABCL688 through CTA-enabling studies. The company has approximately $680 million in available liquidity to execute on its strategy. Platform investments have been substantially completed, and activities have commenced at the new clinical manufacturing facility.

ABCL YoY Financials

Q3 2025 vs Q3 2024 · SEC filings Q3 2024 Q3 2025
$-60,000,000$-30,000,000$0$6.5M$9.0MRevenue$-64,337,045$-76,278,000Operating Income$-64,731,414$-57,119,000Net Income
$-60,000,000$-30,000,000$0RevenueOperating IncomeNet Income

ABCL Revenue by Segment

Licensing and Royalty Revenue$138,000
Research Fees$8.8M
Licensing Revenue

Figures from SEC filings and company reports. Not investment advice.